{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:40:01Z","timestamp":1761100801405},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2005,7,11]],"date-time":"2005-07-11T00:00:00Z","timestamp":1121040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,7,11]],"date-time":"2005-07-11T00:00:00Z","timestamp":1121040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1038\/sj.bmt.1705080","type":"journal-article","created":{"date-parts":[[2005,7,11]],"date-time":"2005-07-11T10:31:57Z","timestamp":1121077917000},"page":"655-661","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Stem cell transplantation for mantle cell lymphoma: if, when and how?"],"prefix":"10.1038","volume":"36","author":[{"given":"T L","family":"Kiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,7,11]]},"reference":[{"key":"BF1705080_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/00062752-200201000-00010","volume":"9","author":"JL Frater","year":"2002","unstructured":"Frater JL, His E . Properties of the mantle cell and mantle cell lymphoma. Curr Opin Hematol 2002; 9: 56\u201360.","journal-title":"Curr Opin Hematol"},{"key":"BF1705080_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/00001622-200109000-00005","volume":"13","author":"JP Leonard","year":"2001","unstructured":"Leonard JP, Schattner EJ, Coleman M . Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001; 13: 342\u2013347.","journal-title":"Curr Opin Oncol"},{"key":"BF1705080_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/00001622-200403000-00004","volume":"16","author":"E Jacobsen","year":"2004","unstructured":"Jacobsen E, Freedman A . An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol 2004; 16: 106\u2013113.","journal-title":"Curr Opin Oncol"},{"key":"BF1705080_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/annonc\/mdi107","volume":"16","author":"AK Ganti","year":"2005","unstructured":"Ganti AK, Bierman PJ, Lynch JC et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005; 16: 618\u2013624.","journal-title":"Ann Oncol"},{"key":"BF1705080_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1023\/A:1008278605751","volume":"8","author":"N Ketterer","year":"1995","unstructured":"Ketterer N, Salles G, Espinouse D et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1995; 8: 701\u2013704.","journal-title":"Ann Oncol"},{"key":"BF1705080_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/oxfordjournals.annonc.a059156","volume":"6","author":"DA Stewart","year":"1995","unstructured":"Stewart DA, Vose JM, Weisenburger DD et al. The role of high dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6: 263\u2013266.","journal-title":"Ann Oncol"},{"key":"BF1705080_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","volume":"22","author":"N Milpied","year":"1998","unstructured":"Milpied N, Gaillard F, Moreau P et al. High dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998; 22: 645\u2013650.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705080_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","volume":"16","author":"AS Freedman","year":"1998","unstructured":"Freedman AS, Neuberg D, Gribben JG et al. High dose chemoradiotherapy and anti B cell monoclonal antibody purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long term remission. J Clin Oncol 1998; 16: 13\u201318.","journal-title":"J Clin Oncol"},{"key":"BF1705080_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1023\/A:1008251301319","volume":"8","author":"P Dreger","year":"1997","unstructured":"Dreger P, von Neuhoff N, Kuse R et al. Sequential high dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol 1997; 8: 401\u2013403.","journal-title":"Ann Oncol"},{"key":"BF1705080_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/sj.bmt.1701033","volume":"21","author":"N Kroger","year":"1998","unstructured":"Kroger N, Hoffknecht M, Dreger P et al. Long term disease free survival of patients with advanced mantle cell lymphoma following high dose chemotherapy. Bone Marrow Transplant 1998; 21: 55\u201357.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705080_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/sj.bmt.1701046","volume":"21","author":"JY Blay","year":"1998","unstructured":"Blay JY, Sebban C, Surbiguet C et al. High dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non Hodgkins lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 1998; 21: 51\u201354.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705080_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1083-8791(00)70030-9","volume":"6","author":"JM Vose","year":"2000","unstructured":"Vose JM, Bierman PJ, Weisenburger DD et al. Autologous stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000; 6: 640\u2013645.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1705080_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","volume":"120","author":"E Vandenberghe","year":"2003","unstructured":"Vandenberghe E, Ruiz de Elvira C, Loberiza FR et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European blood and marrow transplant and autologous blood and marrow transplant registries. Br J Haematol 2003; 120: 793\u2013800.","journal-title":"Br J Haematol"},{"key":"BF1705080_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/sj.bmt.1702135","volume":"25","author":"D Decaudin","year":"2000","unstructured":"Decaudin D, Brousse N, Brice P et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3 year follow up study. Bone Marrow Transplant 2000; 25: 251\u2013256.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705080_CR15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/10428190290026286","volume":"43","author":"R Oinonen","year":"2002","unstructured":"Oinonen R, Jantunen E, Itala M et al. Autologous stem cell transplantation in patients with mantle cell lymphoma. Leuk Lymph 2002; 43: 1229\u20131237.","journal-title":"Leuk Lymph"},{"key":"BF1705080_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.thj.6200007","volume":"1","author":"P Dreger","year":"2000","unstructured":"Dreger P, Martin S, Kuse R et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000; 1: 87\u201394.","journal-title":"Hematol J"},{"key":"BF1705080_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","volume":"71","author":"NS Andersen","year":"2003","unstructured":"Andersen NS, Pedersen L, Elonen E et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Hematol 2003; 71: 73\u201380.","journal-title":"Eur J Hematol"},{"key":"BF1705080_CR18","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression free survival in mantle cell lymphoma \u2013 results of a prospective randomized trial of the European MCL network. Blood 2005; 105: 2677\u20132684.","journal-title":"Blood"},{"key":"BF1705080_CR19","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H et al. Hyper \u2013 CVAD and high dose methotrexate\/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol 1998; 16: 3803\u20133809.","journal-title":"J Clin Oncol"},{"key":"BF1705080_CR20","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1002\/cncr.11838","volume":"98","author":"IF Khouri","year":"2003","unstructured":"Khouri IF, Saliba RM, Okoroji GJ et al. Long term follow up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission. Cancer 2003; 98: 2630\u20132635.","journal-title":"Cancer"},{"key":"BF1705080_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/sj.bmt.1703925","volume":"31","author":"G Hess","year":"2003","unstructured":"Hess G, Flohr T, Huber C et al. Safety and feasibility of CHOP\/rituximab induction treatment followed by high dose chemoradiotherapy and autologous PBSC transplantation in patients with previously untreated mantle cell or indolent B cell non Hodgkins lymphoma. Bone Marrow Transplant 2003; 31: 775\u2013782.","journal-title":"Bone Marrow Transplant"},{"issue":"suppl. 1","key":"BF1705080_CR22","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/sj.bmt.1703296","volume":"29","author":"AM Gianni","year":"2002","unstructured":"Gianni AM, Cortelazzo S, Magni M et al. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002; 29 (suppl. 1): S10\u2013S13.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705080_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/annonc\/mdh090","volume":"15","author":"K Belhadj","year":"2004","unstructured":"Belhadj K, Delfau-Larue MH, Elgnaoui T et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B cell nonHodgkins lymphoma: a single institution study. Ann Oncol 2004; 15: 504\u2013510.","journal-title":"Ann Oncol"},{"key":"BF1705080_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","volume":"16","author":"AS Freedman","year":"1998","unstructured":"Freedman AS, Neuberg D, Gribben JG et al. High dose chemoradiotherapy and anti B cell monoclonal antibody purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long term remission. J Clin Oncol 1998; 16: 13\u201318.","journal-title":"J Clin Oncol"},{"key":"BF1705080_CR25","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","volume":"15","author":"W Brugger","year":"2004","unstructured":"Brugger W, Hirsch J, Grunebach F et al. Rituximab consolidation after high dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective multicenter phase II study. Ann Oncol 2004; 15: 1691\u20131698.","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"BF1705080_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/sonc.2002.30143","volume":"29","author":"J Mangel","year":"2002","unstructured":"Mangel J, Buckstein R, Imrie K et al. Immunotherapy with rituximab following high dose therapy and autologous stem cell transplantation for mantle cell lymphoma. Sem Oncol 2002; 29 (suppl 2): 56\u201369.","journal-title":"Sem Oncol"},{"key":"BF1705080_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/annonc\/mdh069","volume":"15","author":"J Mangel","year":"2004","unstructured":"Mangel J, Leitch HA, Connors JM et al. Intensive chemotherapy and autologous stem cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15: 283\u2013290.","journal-title":"Ann Oncol"},{"key":"BF1705080_CR28","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","volume":"99","author":"AK Gopal","year":"2002","unstructured":"Gopal AK, Rajendran JG, Petersdorf SH et al. High dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158\u20133162.","journal-title":"Blood"},{"key":"BF1705080_CR29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/cncr.10307","volume":"94","author":"TM Behr","year":"2002","unstructured":"Behr TM, Griesinger F, Riggert J et al. High dose myeloablative radioimmunotherapy of mantle cell non Hodgkins Lymphoma with the iodine 131 labeled chimeric anti CD2O antibody C2B8 and autologous stem cell support. Cancer 2002; 94: 1363\u20131372.","journal-title":"Cancer"},{"key":"BF1705080_CR30","first-page":"17a","volume":"17","author":"SK Sohn","year":"1998","unstructured":"Sohn SK, Bensinger W, Holmberg L et al. High dose therapy with allogeneic or autologous stem cell transplantation for relapsed mantle cell lymphoma: The Seattle experience (abstract). Proc Am Soc Clin Oncol 1998; 17: 17a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1705080_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/sj.bmt.1704344","volume":"33","author":"P Mollee","year":"2004","unstructured":"Mollee P, Lazarus HM, Lipton J . Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma? Bone Marrow Transplant 2004; 33: 271\u2013277.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705080_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.bbmt.2004.05.008","volume":"10","author":"A Grigg","year":"2004","unstructured":"Grigg A, Ritchie D . Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004; 10: 579\u2013590.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1705080_CR33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1023\/A:1008380527502","volume":"10","author":"IF Khouri","year":"1999","unstructured":"Khouri IF, Lee MS, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999; 10: 1293\u20131299.","journal-title":"Ann Oncol"},{"key":"BF1705080_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/10428190400015022","volume":"46","author":"J Rifkind","year":"2005","unstructured":"Rifkind J, Mollee P, Messner H, Lipton J . Allogeneic stem cell transplantation for mantle cell lymphoma \u2013 does it deserve a better look? Leuk Lymphoma 2005; 46: 217\u2013223.","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 2","key":"BF1705080_CR35","first-page":"9a","volume":"13","author":"JO Armitage","year":"2002","unstructured":"Armitage JO . Allotransplants for mantle cell lymphoma. Ann Oncol 2002; 13 (Suppl 2): 9a.","journal-title":"Ann Oncol"},{"key":"BF1705080_CR36","doi-asserted-by":"crossref","first-page":"255a","DOI":"10.1182\/blood.V104.11.255.255","volume":"104","author":"LL Popplewell","year":"2004","unstructured":"Popplewell LL, Nademanee A, Carter N et al. Autologous vs allogeneic cell transplantation for mantle cell lymphoma (MCL): outcomes over a 10-year period at City of Hope (abstract). Blood 2004; 104: 255a.","journal-title":"Blood"},{"key":"BF1705080_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.bmt.1701540","volume":"23","author":"A Grigg","year":"1999","unstructured":"Grigg A, Bardy P, Byron K et al. Fludarabine-based nonmyeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant 1999; 23: 107\u2013110.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705080_CR38","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","volume":"21","author":"IF Khouri","year":"2003","unstructured":"Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407\u20134412.","journal-title":"J Clin Oncol"},{"key":"BF1705080_CR39","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","volume":"104","author":"MB Maris","year":"2004","unstructured":"Maris MB, Sandmaier BM, Storer BE et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2\u2009Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535\u20133542.","journal-title":"Blood"},{"key":"BF1705080_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/1096-8652(200009)65:1<75::AID-AJH14>3.0.CO;2-L","volume":"65","author":"SK Sohn","year":"2000","unstructured":"Sohn SK, Baek JH, Kim DH et al. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. Am J Hematol 2000; 65: 75\u201380.","journal-title":"Am J Hematol"},{"key":"BF1705080_CR41","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","volume":"104","author":"E Morris","year":"2004","unstructured":"Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865\u20133871.","journal-title":"Blood"},{"key":"BF1705080_CR42","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","volume":"100","author":"SP Robinson","year":"2002","unstructured":"Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and bone marrow transplantation. Blood 2002; 100: 4310\u20134316.","journal-title":"Blood"},{"key":"BF1705080_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","volume":"11","author":"YL Kasamon","year":"2005","unstructured":"Kasamon YL, Jones RJ, Diehl LF et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005; 11: 39\u201346.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1705080_CR44","first-page":"482a","volume":"96","author":"E Vandenberghe","year":"2000","unstructured":"Vandenberghe E, Ruiz de Elvira C, Isaacson P et al. Does transplantation improve outcome in mantle cell lymphoma (MCL)?: a study from the EBMT. Blood 2000; 96: 482a.","journal-title":"Blood"},{"key":"BF1705080_CR45","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1083-8791(01)70016-X","volume":"7","author":"JG Berdeja","year":"2001","unstructured":"Berdeja JG, Jones RJ, Zahurak ML et al. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant 2001; 7: 561\u2013567.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1705080_CR46","doi-asserted-by":"crossref","first-page":"622a","DOI":"10.1182\/blood.V104.11.622.622","volume":"104","author":"SP Robinson","year":"2004","unstructured":"Robinson SP, Schmitz N, Taghipour G et al. Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant related mortality and a poor outcome in patients with chemoresistant disease (abstract). Blood 2004; 104: 622a.","journal-title":"Blood"},{"key":"BF1705080_CR47","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"5","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression free survival. J Clin Oncol 2002; 5: 1288\u20131294.","journal-title":"J Clin Oncol"},{"key":"BF1705080_CR48","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone significantly improves response and time to treatment failure, but not long term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). J Clin Oncol 2005; 23: 1984\u20131992.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705080","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:32:11Z","timestamp":1648081931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,11]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,10,1]]}},"alternative-id":["BF1705080"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705080","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,11]]},"assertion":[{"value":"1 June 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}